Notably, we demonstrated that the inhibition of Wnt/β-catenin signaling pathway significantly abrogated the upregulation of PD-L1 in BMFs stimulated by cancer cells and remarkably boosted the therapeutic effects of aPD-L1 treatment by overcoming the immunosuppressive status in BMF-rich tumors. This evidence concerns the gene CD274 and cancer.